Search

Your search keyword '"Tony Marson"' showing total 3 results
Start Over Author "Tony Marson" Journal trials
3 results on '"Tony Marson"'

1. Protocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: the EPilepsy outcome Set for Effectiveness Trials Project (EPSET)

Author

James W. Mitchell, Adam Noble, Gus Baker, Rachel Batchelor, Francesco Brigo, Jakob Christensen, Jacqueline French, Antonio Gil-Nagel, Alla Guekht, Nathalie Jette, Reetta Kälviäinen, John Paul Leach, Melissa Maguire, Terence O’Brien, Felix Rosenow, Philippe Ryvlin, Phil Tittensor, Manjari Tripathi, Eugen Trinka, Samuel Wiebe, Paula R. Williamson, and Tony Marson

Subjects
Core outcome set, Epilepsy, Consensus, Delphi study, Treatment outcome, Clinical trials, Medicine (General), R5-920
Abstract

Abstract Background A Core Outcome Set (COS) is a standardised list of outcomes that should be reported as a minimum in all clinical trials. In epilepsy, the choice of outcomes varies widely among existing studies, particularly in clinical trials. This diminishes opportunities for informed decision-making, contributes to research waste and is a barrier to integrating findings in systematic reviews and meta-analyses. Furthermore, the outcomes currently being measured may not reflect what is important to people with epilepsy. Therefore, we aim to develop a COS specific to clinical effectiveness research for adults with epilepsy using Delphi consensus methodology. Methods The EPSET Study will comprise of three phases and follow the core methodological principles as outlined by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative. Phase 1 will include two focused literature reviews to identify candidate outcomes from the qualitative literature and current outcome measurement practice in phase III and phase IV clinical trials. Phase 2 aims to achieve international consensus to define which outcomes should be measured as a minimum in future trials, using a Delphi process including an online consensus meeting involving key stakeholders. Phase 3 will involve dissemination of the ratified COS to facilitate uptake in future trials and the planning of further research to identify the most appropriate measurement instruments to use to capture the COS in research practice. Discussion Harmonising outcome measurement across future clinical trials should ensure that the outcomes measured are relevant to patients and health services, and allow for more meaningful results to be obtained. Core Outcome Set registration COMET Initiative as study 118 .

Published
2022
Full Text
View/download PDF

2. The trials and tribulations of accessing data from routine sources

Author

Graham Powell, Paula R Williamson, Catrin Tudur-Smith, Dyfrig A. Hughes, and Tony Marson

Subjects
medicine.medical_specialty, business.industry, Big data, Alternative medicine, Medicine (miscellaneous), Linked data, medicine.disease, Bioinformatics, law.invention, Randomized controlled trial, Data Applied, law, Poster Presentation, medicine, Revenue, Pharmacology (medical), Observational study, Medical emergency, Limited evidence, business
Abstract

There are a number of administrative datasets that routinely record information on individuals in the UK. Such routine or ‘Big Data’ sources record specified data variables that are largely limited to those that enable the intended objectives of the data holder. Routine sources include clinical datasets such as Hospital Episode Statistics (HES) and the Clinical Practice Research Datalink (CPRD). In addition, non-health data is recorded by the Department of Work and Pensions (DWP), HM Revenue and Customs (HMRC) and The Driving and Vehicle Licensing Authority (DVLA) in order to meet the specified objectives of each authority. Routine data applied to clinical research is potentially cost and resource-use effective. Clinical sources of data such as HES and CPRD are commonly accessed to provide data for retrospective observational and record-linkage studies and there are many published examples. However, there is limited evidence on the use of routine data in prospective studies, particularly randomised controlled trials (RCTs). This on-going project aims to assess the feasibility, accuracy, reliability and additional benefits of using data from routine sources for patients participating in the Standard and New Antiepileptic Drugs II RCT. Clinical and health economic outcomes will be examined from sources including HES, CPRD, DWP, HMRC and DVLA and assessed in comparison to data obtained from traditional RCT methods. This presentation will narratively summarise the methods of access, application procedures and limitations encountered thus far with accessing individual-level, linked data from the listed routine data sources.

Published
2015
Full Text
View/download PDF

3. Simulation study - handling missing covariates in the context of external validation

Author

Paula R Williamson, Laura J. Bonnett, Catrin Tudur-Smith, and Tony Marson

Subjects
lcsh:R5-920, business.industry, External validation, Medicine (miscellaneous), Context (language use), Machine learning, computer.software_genre, Missing data, Poster Presentation, Covariate, General practice, Data analysis, Prognostic model, Medicine, Pharmacology (medical), Artificial intelligence, Single trial, lcsh:Medicine (General), business, computer
Abstract

Objectives Before a predictive or prognostic model, often developed using data from clinical trials, can be introduced into general practice, it needs to be externally validated to ensure that it performs satisfactorily in data sets that are fully independent of the development data. Various methods exist to handle covariates with missing data and many of these are regularly employed in the analysis of data from a single trial. We propose that several of these strategies may be adapted to handle covariates with every entry missing in the context of external validation.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results